And so, that just basically reflects who we enroll in clinical trials. I'm sure many of you have heard the conversations about the lack of representation from different minority backgrounds in clinical trials. This issue also affects the genomic studies we conduct to understand cancer, as we don't enroll enough individuals.
For instance, with the TCGA, it is evident that over 75% of their participants are of European ancestry. This trend is similarly observed with the Project genie. However, it is crucial to enroll individuals from diverse backgrounds because there are clear differences that need to be accounted for.